Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 5Genitourinary 3Other solid neoplasm 2Head & Neck 2Gynecologic 2Sarcoma 1Dermatologic 1CNS 1Breast 1

Conditions

Recurrence 1Glioblastoma 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × zimberelimab × CNS × Clear all
NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Yale University

Phase EARLY_PHASE1 Active not recruiting
46 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡